Present the PICO format for each of the following trials: (1) SPARCL – adults aged 45‑80 years with a recent ischemic stroke or transient ischemic attack, LDL‑C 100‑190 mg/dL, no known coronary artery disease, peripheral arterial disease, atrial fibrillation, prosthetic heart valves, or significant mitral stenosis; intervention atorvastatin 80 mg daily versus placebo; outcome first recurrent stroke (ischemic or hemorrhagic). (2) Treat‑Stroke‑to‑Target – adults aged 18‑85 years with an acute cerebral infarction within 3 months or a high‑risk transient ischemic attack; intervention high‑intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20 mg) titrated to LDL‑C <70 mg/dL with ezetimibe added if needed versus moderate‑intensity statin therapy (simvastatin 20‑40 mg or pravastatin 40 mg) titrated to LDL‑C 90‑110 mg/dL; outcome major cardiovascular events including recurrent ischemic stroke, myocardial infarction, or vascular death.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PICO Formats for SPARCL and Treat-Stroke-to-Target Trials

(1) SPARCL Trial

Population:

  • Adults aged 45-80 years
  • Recent ischemic stroke or TIA (1-6 months prior to enrollment) 1
  • LDL-C 100-190 mg/dL
  • Exclusions: No known coronary heart disease, peripheral arterial disease, atrial fibrillation, prosthetic heart valves, or clinically significant mitral stenosis 1

Intervention:

  • Atorvastatin 80 mg daily 1

Comparison:

  • Placebo 1

Outcome:

  • Primary: First recurrent stroke (ischemic or hemorrhagic) 1
  • Results: During median 4.9-year follow-up, stroke occurred in 11.2% receiving atorvastatin versus 13.1% receiving placebo (adjusted HR 0.84,95% CI 0.71-0.99, P=0.03) 1
  • The trial demonstrated 218 ischemic strokes and 55 hemorrhagic strokes in the atorvastatin group versus 274 ischemic strokes and 33 hemorrhagic strokes in placebo 2

(2) Treat-Stroke-to-Target (TST) Trial

Population:

  • Adults aged 18-85 years 1
  • Acute cerebral infarction within 3 months OR high-risk TIA (defined as arm and leg motor deficit or speech disturbance lasting >10 minutes) 1
  • Evidence of cerebrovascular or coronary-artery atherosclerosis 3

Intervention:

  • High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20 mg) titrated to LDL-C <70 mg/dL 1
  • Ezetimibe added if needed to achieve target 1

Comparison:

  • Moderate-intensity statin therapy (simvastatin 20-40 mg or pravastatin 40 mg) titrated to LDL-C 90-110 mg/dL 1

Outcome:

  • Primary: Major cardiovascular events including recurrent ischemic stroke, myocardial infarction, or vascular death 1
  • Results: During median 3.5-year follow-up, the composite primary endpoint occurred in 8.5% in the lower-target group versus 10.9% in the higher-target group (adjusted HR 0.78,95% CI 0.61-0.98, P=0.04) 3
  • Mean achieved LDL-C was 65 mg/dL in the lower-target group versus 96 mg/dL in the higher-target group 3

Key Clinical Implications

Both trials established the foundation for current guideline recommendations 1:

  • SPARCL demonstrated benefit of high-intensity statin therapy versus placebo in stroke patients without coronary disease
  • TST confirmed that targeting LDL-C <70 mg/dL is superior to targeting 90-110 mg/dL for preventing major cardiovascular events
  • TST validated the use of ezetimibe as second-line therapy to achieve LDL-C targets 1

References

2
Research

High-dose atorvastatin after stroke or transient ischemic attack.

The New England journal of medicine, 2006

3
Research

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.

The New England journal of medicine, 2020

Related Questions

Should I increase atorvastatin (Lipitor) from 40 mg to 80 mg daily in a patient with a recent stroke whose LDL cholesterol is above the low‑risk target?
Is high‑intensity atorvastatin (80 mg) appropriate for secondary prevention after an ischemic stroke in an adult without contraindications?
Should a patient with a recent ischemic stroke be started on a high‑intensity statin (e.g., atorvastatin) for secondary prevention?
When is atorvastatin (lipitor) 40mg used instead of 80mg in patients with a history of stroke or transient ischemic attack (TIA), particularly in those with impaired renal function, diabetes, or aged 75 years or older?
What type of language does the statement 'Take atorvastatin (statin) by mouth once a day to help reduce your risk of cerebral vascular accident (CVA) and myocardial infarction (MI)' represent?
In a 30-year-old female (~102 lb) presenting with alcohol‑withdrawal tremor, nausea, anxiety, tachycardia and hypotension after binge drinking, who has received lorazepam (Ativan) 2 mg PO, chlordiazepoxide 50 mg PO, lorazepam 2 mg IV, 1 L normal saline, 2 L lactated Ringer’s, and ondansetron (Zofran) 4 mg IV twice with improvement to a Glasgow Coma Scale of 14, what is the best next step in management?
What randomized controlled trials support the use of high‑intensity statins for preventing recurrent ischemic stroke in adults?
I have had superior mesenteric artery syndrome for six years without a nasogastric (NG) tube; how do I arrange for nasogastric/nasojejunal tube placement?
What is the recommended treatment for renal potassium loss?
In complete (third-degree) heart block, what is the typical atrial rate?
How do we measure serum osmolality?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.